"Progenza includes secretions from MSCs that improves viability and functionality of the cells during the freezing and thawing process. Regeneus has shown that a combination of cells and secretions has a more powerful therapeutic effect than cells alone."
RGS's secretions technology may turn out to be a unique product platform in regenerative medicine, and probably the key reason why AGC did a JV deal with Regeneus.
REG's secretions technology came in 2015 via a collaboration with Macquarie University.
